TOMSK, Sep 21 – RIA Tomsk. Scientists of the Institute for Problems of Chemical and Energetic Technologies (IPCET) SB RAS (Biysk) with the assistance of colleagues from Tomsk State University (TSU) developed medicine for treatment with lack of side effect; glyoxal became raw materials for medicine, the press service of the higher education institution reported on Wednesday.
Glyoxal is a substance which industrial technology of synthesis is developed by chemists of TSU. In 2009 in Tomsk the Russian Federation's first glyoxal production plant was opened. It is used for production of new generation of rocket fuel, medical supplies and thousands of other materials and substances.
"High-energy compounds are also made on the basis of glyoxal. We withdraw a small part of substance at the intermediate stage of synthesis, finish it and receive medicine with fine pharmacological characteristics", – the director of IPCET SB RAS Sergey Sysolyatin is quoted in the message.
It is specified that on the basis of the Tomsk scientific research institute of pharmacology and regenerative medicine preclinical tests of the new medicine – tiovurcin were carried out. They showed that the medicine stops pains of various origin, has longer period of action, than other anesthetics of medicine, but at the same time it doesn't make toxic impact on an organism."According to the expert opinion, tiovurcin conforms to the requirements of the fourth class of danger – "low-dangerous substances". Extent of its toxic impact on an organism is comparable unless with a hyperalimentation. At long injection of drug (28 days) medicinal dependence doesn't develop, there is no influence on respiration, there is no stimulating effect on the central nervous system", – it is said in the report.
Preclinical testing of the new medicine are on a closing stage. The patent for the development is already taken out. The joint project of the Biysk and Tomsk scientists is planned to be realized within the Pharma 2020 program.